Neuroscience is among the most commercially complex categories in specialty pharma – long development timelines, rapidly evolving competitive landscapes, and prescriber behavior that shifts in ways claims data consistently misses. Alzheimer’s disease, generalized myasthenia gravis, multiple sclerosis, migraine, and emerging psychiatric indications each carry distinct market dynamics, distinct prescriber communities, and distinct access challenges.

Spherix has tracked Neuroscience (formerly tracked as CNS) continuously for more than a decade, building one of the most tenured research programs in the category. The team combines seven dedicated Neuroscience specialists with a KOL advisory panel and a community of practicing neurologists, psychiatrists, and access decision-makers, screened and maintained continuously by Spherix’s own Community team – not a rented panel. Research waves include up to 250 Neuroscience specialists per quarterly US wave, with semiannual international waves across EU4+UK, Canada, Brazil, China, and Japan. The result is intelligence that reflects how Neuroscience markets actually behave, not how they are described in published literature or sponsored research.